NCT01218802View on ClinicalTrials.gov

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

PHASE2CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
HIV InfectionsHeart Disease
Interventions
DRUG

Rosuvastatin 10 mg. daily for 96 weeks

Participants will take Rosuvastatin 10 mg. daily for 96 weeks.

DRUG

Placebo

participants will take a sugar pill daily for 96 weeks

Trial Locations (1)

44106

University Hospitals of Cleveland Case Medical Center, Cleveland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER